Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer
D Isla, J De Castro, O Juan, S Grau… - ClinicoEconomics …, 2016 - Taylor & Francis
Objectives Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) are an
established treatment for advanced non-small cell lung cancer (NSCLC) with EGFR …
established treatment for advanced non-small cell lung cancer (NSCLC) with EGFR …
Il costo degli eventi avversi associati ad afatinib, erlotinib e gefitinib nel trattamento del tumore del polmone non a piccole cellule con mutazione EGFR
A Favaretto, F Grossi, A Morabito… - Global & Regional …, 2017 - journals.sagepub.com
Costs of adverse events associated with afatinib, erlotinib, and gefitinib first-line therapies in
advanced non-small-cell lung cancer harboring EGFR-activating mutations Introduction …
advanced non-small-cell lung cancer harboring EGFR-activating mutations Introduction …
Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
O Arrieta, R Catalán, S Guzmán-Vazquez, F Barrón… - BMC cancer, 2020 - Springer
Abstract Background Tyrosine-kinase inhibitors (TKIs) have become the cornerstone
treatment of patients with non-small cell lung cancer that harbor oncogenic EGFR mutations …
treatment of patients with non-small cell lung cancer that harbor oncogenic EGFR mutations …
Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive …
M Kimura, F Yasue, E Usami… - Molecular and …, 2018 - spandidos-publications.com
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib,
erlotinib and afatinib are standard first-line treatments for EGFR gene mutation-positive non …
erlotinib and afatinib are standard first-line treatments for EGFR gene mutation-positive non …
[HTML][HTML] Economic analysis of first-line treatment with erlotinib in an EGFR-mutated population with advanced NSCLC
A Vergnenegre, B Massuti, F de Marinis… - Journal of Thoracic …, 2016 - Elsevier
Introduction The cost-effectiveness of first-line tyrosine kinase inhibitor therapy in epidermal
growth factor receptor gene (EGFR)-mutated advanced-stage non–small cell lung cancer …
growth factor receptor gene (EGFR)-mutated advanced-stage non–small cell lung cancer …
Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
MS Holleman, MJ Al, R Zaim, HJM Groen… - The European Journal of …, 2020 - Springer
Objectives To compare the cost-effectiveness of first-line gefitinib, erlotinib, afatinib, and
osimertinib in patients with non-small cell lung cancer (NSCLC) harbouring epidermal …
osimertinib in patients with non-small cell lung cancer (NSCLC) harbouring epidermal …
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
M Takeda, I Okamoto, K Nakagawa - Lung Cancer, 2015 - Elsevier
Objectives Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)–
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …
Cost-effectiveness analysis of afatinib, erlotinib, and gefitinib as first-line treatments for EGFR mutation-positive non-small-cell lung cancer in Ontario, Canada
Objective The objective of this study was to compare the cost effectiveness of first-line
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for the treatment of …
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for the treatment of …
The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first-and second …
J Subramanian, AW Fernandes, F Laliberté, M Pavilack… - Lung Cancer, 2019 - Elsevier
Objectives Clinical trials with first-and second-generation epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) reported severe adverse events (SAEs) in 6%–49 …
tyrosine kinase inhibitors (EGFR-TKIs) reported severe adverse events (SAEs) in 6%–49 …
[HTML][HTML] Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR …
Introduction Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …